In addition, to further explore the predictive value of MOXD1 regarding the response to immunotherapy in bladder cancer patients, we utilized the Comprehensive Analysis on Multi-Omics of Immunotherapy in Pan-cancer (CAMOIP) database to analyze the immune characteristics of the patients in the groups with high and low expression of MOXD1. Here, MOXD1 is linked to urinary bladder carcinoma.